Lunai Bioworks Renames, Streamlines Capital Structure, and Focuses on AI-Powered Therapeutics and Biodefense

Lunai Bioworks has rebranded from Renovaro Inc. to Lunai Bioworks, reflecting a focus on AI-powered therapeutics and biodefense. The company has adopted a new corporate identity and ticker symbol "LNAI" and completed a 10:1 reverse stock split to enhance capital efficiency. Recent milestones include the launch of a transformer-based platform, advancements in a Parkinson's biomarker program, and platform validation through a competitive NIH grant. Lunai is committed to capturing biological signals at scale, decoding them using AI, and validating them quickly in model systems.

Lunai Bioworks (NASDAQ:LNAI), formerly known as Renovaro Inc., has announced a significant transformation, unveiling a new corporate identity and completing a 10:1 reverse stock split. The rebranding, which took effect on September 30, 2025, reflects the company's strategic focus on AI-powered drug discovery and biodefense. The reverse stock split reduces outstanding shares from 231.8 million to 23.2 million, enhancing capital efficiency and aligning with Nasdaq's minimum bid price requirements Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense^[1].

The rebranding from Renovaro Inc. to Lunai Bioworks signifies a strategic pivot. The company is now positioned at the intersection of AI, drug development, and biodefense, sectors with significant government and private funding. The new corporate identity underscores Lunai's commitment to capturing biological signals at scale, decoding them using AI, and validating them quickly in model systems. This transformation positions the company as a category leader in artificial intelligence, healthcare, and global security.

Recent milestones include the launch of a proprietary transformer-based platform for neurotoxicity intelligence, advancements in a Parkinson's biomarker program through subsidiary BioSymetrics, and securing a multi-year NIH STTR grant. The Augusta platform, which integrates AI into therapeutics and biomarker intelligence, aims to advance precision neurology. The company's scientific developments show meaningful progress, addressing critical safety challenges in drug development and enabling more targeted therapies.

The biodefense angle is particularly strategic, opening access to government contracts and grants. However, investors should note that Lunai Bioworks remains pre-revenue, with a focus on platform development rather than late-stage candidates nearing commercialization.

The reverse stock split, which mathematically increases the per-share price by a factor of ten while keeping market capitalization unchanged, appears designed to maintain Nasdaq listing compliance. This financial engineering follows periods of significant share price deterioration and effectively dilutes shareholders' ownership percentage.

Lunai Bioworks' transformation represents a strategic refocus on AI drug discovery and biodefense, creating a clearer investment thesis. The company remains committed to ethical innovation, translational science, and scalable collaboration, positioning itself to lead the next wave of AI-driven breakthroughs in medicine and biodefense.

References

Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense^[1] https://www.stocktitan.net/news/LNAI/lunai-bioworks-unveils-new-corporate-identity-streamlined-capital-p730yocfkkud.html